Joop M A Van Gerven (Joop van Gerven, Joop M A van Gerven)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 9

Top Topics

Randomized Controlled Trial

Top Venues

British journal of clinical pharmacology

Clinical and translational science

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Ingrid W Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop M A Van Gerven, Geert Jan Groeneveld, Rob G J A Zuiker
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clinical and translational science 17 (7) (2024)
Ingrid W Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop M A Van Gerven, Geert Jan Groeneveld, Rob G J A Zuiker
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clinical and translational science 17 (7) (2024)
Ingrid W Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop M A Van Gerven, Geert Jan Groeneveld, Rob G J A Zuiker
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clinical and translational science 17 (7) (2024)
Anne Catrien Baakman, Carmen Gavan, Lotte van Doeselaar, Marieke de Kam, Karen Broekhuizen, Ovidiu Bajenaru, Laura Camps, Eleonora L Swart, Kees Kalisvaart, Niki Schoonenboom, Evelien Lemstra, Philip Scheltens, Adam Cohen, Joop M A Van Gerven, Geert Jan Groeneveld
Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease. British journal of clinical pharmacology 88 (6) (2022)
Maurits F J M Vissers, Adam F Cohen, Joop M A Van Gerven, Geert Jan Groeneveld
The impact of the global COVID-19 pandemic on the conduct of clinical trials: Return to normalcy by considering the practical impact of a structured ethical analysis. British journal of clinical pharmacology 87 (3) (2020)
Joop M A Van Gerven, Milton Bonelli
Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. British journal of clinical pharmacology 84 (7) (2018)
Ricardo Alvarez-Jimenez, Ellen P Hart, Samantha Prins, Marieke de Kam, Joop M A Van Gerven, Adam A Cohen, Geert Jan Groeneveld
Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses. British journal of clinical pharmacology 84 (5) (2018)
Joop M A Van Gerven, Adam A Cohen
Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects. British journal of clinical pharmacology 84 (7) (2018)
Clemens Muehlan, Jules Heuberger, Pierre-Eric Juif, Marie Croft, Joop M A Van Gerven, Jasper Dingemanse
Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study. Clinical pharmacology and therapeutics 104 (5) (2018)